welcome and Michaella, QX Thanks, our call. to
in COVID-XX to elongate two our highlight taken results We’ll cash QX the we’ve runway discuss and During progress made over will we years. light the pandemic. last time together, share the first actions of our our
the and our clinical, economic apart set propositions We us value will clearly marketplace. that strategic define in
in we then results, driving MRIdian therapy more delve how we become We cancer forward to what answering go more our and utilization greater will financial types. and into your into questions. of deeply a will SMART, our complex first-line SBRT, certain to Zach the trend blueprint call we’re toward look deeply
from If the X, on next you’re and on our Investor our not we webcast, patient our meaningful slides month, anticipate site. prove to what Slide milestone. a We be Relations mission treat is XX,XXXth will treat referring the presentation to can’t. others that I’ll On
X,XXX We have the on of change and and clinical paradigm is experiences also currently This [ph] care. more compelling preponderance efforts than our which of critical and published body radiation patient the represent growing outcomes, therapy. MRI-guided literature to of data improve to
by a drive ago, and for been We out set XX. were to Two being X. was therapy UMC build foundation that XX both Prostate set times. frame. corresponding in care to timeframe. the reduce We more capitalize cancers. times cusp adaptive lives growth. fully and about patients. decrease to treated treating set to to and half straightforward our Back had is number patients; increase out of treated averaged time Turning we that XX- XX Slide and in to then, have adoption, would our the minutes. to cancers recent cancer to cancer years installations Pancreas improve in then improve XX out XX-minute XX,XXXth. solid the on strove we treatments XX about XX Today, out pancreas cancer minutes. We XX; Amsterdam treatment difficult install about days, set we’re customers; of Then, today, over about our today, team the on of X,XXX treated to the We our
customers MRIdian. so across SMART are treating commissioning. Today, in types sub ago, to cancer fashion was XX-minute years customers MRIdian we’re speed in can upon were of fully-adapted fractions. there up bringing treat customers how Two several variability they terms utilizing Now, in
clinical our with today. more improvements, future. dive subject benefits Similarly, pipeline great deep proving of our great MRIdian fruit, innovation has the This borne Our of SMART. come the is pipeline driven has to the in
on Slide four in QX received to turn X. MRIdian Let’s We results orders the quarter.
pleased customer series we’ve is webinar example in highlighted customer such value the In of the clinical, and We MRIdian. with with ways of environment. and as the We’ve economic new to adapted this interact, strategic over engagement views. believe already interest. X,XXX of level growing light our created series. challenging of evidence We’re this The in resulted customer has result unique prospective engagement of customers, and recent partnership and
to recognized revenue speeds from market units. market. approximately differing forward, Generally, at are to primarily We revenue. two $XX from albeit Turning installations million moving
modest remains U.S. seeing and the of are including impact restrictions. travel much while or Europe, significantly the COVID-XX, delayed due to progress We Asia in hold on of
we executing and we salary reducing announced to approximately of the investing We our appropriately reduce and utilization, customers in a we financially. elongate small of in In our and spend used our Board recently plan balance $XX.X but these announced striking further by and are our cash million business We action, we’re Regarding on believe team Back we quarter, previously the difficult furloughed are actions recover team. additional believe capital. April, necessary would while take workforce take while took preserving runway. right management reductions, that our XX%. our percentage to our
our therapy and and Importantly, adoption in clinical budgeting innovation driving increased investment while prioritizing preserving we capital. pipeline, are
next our and recover advance business of phase the in market its to that expect growth. We will
However, it’s to difficult predict the timeline.
summary, the ViewRay members including the pandemic. providing goal this senior flexibility, providing believe as period our implemented have to several Officer, leaner program of retaining these Matin, with stronger of of organization. emerge Shar positioned company leadership from through key and a with part As the team, and the In we we actions Operating talent Chief optionality a
on X Now, through our step are customers. resonating three propositions value with Slide me let that
difficult-to-treat ubiquitous lung to breast foremost, our to and and reoptimize risk, pancreas, cancers First to at Oligomets, deliver outcomes prostate. both fractions. reduce on healthy tough-to-treat clinically thus like precision such and and accuracy customers lack the conventional shrink the spare our enables of table dose of linacs. customers are and safely as organs cancers deemed tissues in untreatable MRIdian to margins, escalate central Often, are and cancers, able and better due
on the customers programs lead to conventional benefiting new our Second, programs their are changes for patients their referral establishing treated patterns, travel differentiate front, linacs. respective MRIdian They and in generally cancer patients on MRIdian motivated from is for markets not helping treatment. by are as strategic
SMART, IMRT that therapy. adaptive SBRT We care, are to – MR-guided to from radiation simple stereotactic next-generation others trend driving the call I’ll this – MRIdian SBRT offer
were MRIdian as are customers by our function driving step conventional XxX Just SMART. to x-rays linacs, change obsoleted another
throughput total are appropriate candidates from ability flow addressable in for front, not new catchment economic generally the economic the customers and These realizing linacs, patients new their outside Third, improvements patients reimbursement. annual on our conventional from market. expand improvements adaptive to their area, patient traveling
seeing several current these propositions install are value customers or to MRIdian We purchase prompt additional systems.
will into to our proposition. X. dive we value Moving Slide deep clinical Today,
considered zones. customers to clinical Our believe foundation of has early and led on clarity what Voice on the data conventional proposition, This value that be promise Slide no-fly be areas produced drive in patients of our work you’ll on paradigm see will of Customer MRIdian. linacs this of the new previously of to On wouldn’t AHA even unlocked the our treating we treated X, data care.
Grade whereas and doses ultra-central toxicities lung, linacs grade grade XX%, lung clinical death. have example, with shown or or X% five in up only X conventional ablative MRIdian higher central studies three to toxicity delivered For higher and toxicity, even with or
is Let just cardiac this heart. me the clinical surrounding sarcoma, X, are customers few of groundbreaking Slide our tissue the the a highlight On to our case first capabilities a light. tumor bring cases within a located doing to connective
on patient this old an the would conventional date. patient dose Slide with case, but via toxicity kidney is of child open heart extremely not deliver XX, as our next to primary prolonged cancer cancer. safely therapy inoperable rare is patient tumor heart on by or even quality type. to the a today come of of transplant. MRIdian and courses with deadly with rate surgery, radiation undergo tumor. would have XX%, and kidney been and a the MRIdian over for liver primary SMART likely surgery contributed care with tumor. a shrink Treatment, standard customer Use well was high-end of life. a SMART in case, Slide of shrinking risk ablative and MRIdian, is either Before can Tissue a a The the to complication the is The receive toll signs on The typically heavy considered; on is a able to case linac, radiation last is toxicity XX-month sensitive, this XX surrounding no factor doing
says, include patient was Tumor curative via the and technology clinical you eight to kinds sums customer patients quote, treat MRIdian with of Orlando achieved of that our radiation at Slide and these achieve, more It’s I care noninvasive impressed retain with being upgrade patients short safely. how deliver so function. current first kidney standard this note was doses, of Kelly toxicity, to On of not Our therapy can kidney Health includes imaging that on succinctly. primary and frames intent for There Dr. world, started latest cancer. what XX, treatment, delivered SMART tumor no toxicity representing the low much SMART MRIdian, his weekly He "When important and the second. to a programs MRIdian at control are to allows was around does experience up I system treating our by on precisely basis courses per able ablative dozens no at done across radiation sites. cases
the safety changes to two The On therapy," have at your these could continued share practice. treat forward. As clinical changes treat clinical inspiring a you Slide candidate allows who treated early backdrop primary for end patients I MRIdian, to cases, I you XX, and of I’ll It look the realized MRIdian you precision our with whom as with before. never and data goals, radiation moving quote.
the expansion new and is programs. or goal utilizing complex SBRT, our expand Our types This is cancer new utilization SMART. in of within first both customers therapy opening MRIdian current MRIdian to
to less first-line therapy treatments in considered our Second, targeted is over time, be strategy more invasive replace precise, a cancers. and
also is of decisions. MRIdian unlock first the data require data payer to efficacy support treatment is goal patient SMART. safety new use to used Physicians cross-specialty Our boards. expanding through This tumor and
target our landscape. trials over areas three XX more have ongoing are studies goal. There I’ll cancer to with four in highlight first sites across achieve We XX the than
inoperable First borderline is our study resectable for patients. pancreas and SMART
median retrospective dose repeated series, feasibility the three of patients data of in came form been outcomes by early high-low doubled grade Those at U. now of a Our in use favorable MRIdian separate series the the MRIdian SMART have treated eliminating Wash about survival while where toxicities.
in trial SMART of patient at population. Our MRIdian this prospective aims and further expansion validation
therapy course requires targeting Currently, Second courses XX when courses prostatectomy. opens of treatment, therapy is seven- the a eight-week after the of a door conventional treatment, after long over radiation fractions of fractions to is to over SMART study the application week. prostatectomy, more five one short radiation MRIdian just recommended or period of time. of
two-pronged we results than expect feasibility and We currently that of hypofractionation on for controlled paradigm a SMART care. conventional have randomized initial two, linac. data to year. a changing MRIdian this study delivers Number enrolling help equal a Number is one, next trial UCLA, demonstrate better a at approach sometime or
responder. Finally, on half that non-responder to immunotherapy, with therapy patients the to treatment. XX% radiation for has data Almost a about cancer cancer of may the combination cutting edge be are shift we respond care but into able shown are embarking only Early therapy. this candidates of all
However, has doses lesions Phase conventional Thus, will be means. demonstrate may seek the located limited high has cancer Miami second radiation making immunotherapy of options. will ability therapy. we are If highlights with ablative trial, patients a Institute organs. SMART near doses MRIdian our tumor this again, to a XX create require to therapy, order new II which may between to that their Slide first-line MRIdian these SMART improve facilitate and expect often synergy opened critical response. to in successful, treatment goal
like studies. to point I’d important out tow Here,
for is first pancreatic The cancer.
toward in candidates. simple surgical MRIdian benefits the We to operable patients. SMART candidates for as SBRT MRIdian set for multi-institutional this a have show study MRIdian will first-line of option as and an borderline or surgical to step randomize patients trial view Europe convert best resectable patients out and A inoperable to SMART into important supportive establishing both We care. preoperative
data tougher smaller intact opened on up cohort to used but clinical obtained published our discussed MRIdian Also, clear, with previously open are a data, were patients, therapy for prospective than were SBRT at data. studies. prostate. a to treatment. aim that complications. prostate It SMART need Building and studies simple no for markers, has or additional the I five This provide treatment without results postoperative sustained a implanted other an for such toxicity much patients. Tumor than of margins also with or their a controlled but we demonstrated be MR-guided assess markers. study radiation little fractions patients evidence hypofractionation as prostate, the at these conventional procedure high-risk impressive trial to implanted XX in intact in invasive would not X conventional taking patients, To in results therapy safer UMC about head-to-head largest only also this versus one-year randomized SBRT trial treated MRIdian UCLA Amsterdam with generally, for for associated linac. These one-year XX to first efforts Second, fiducial zero X XX% Grade grade for the comparable trial follow-up. versus MRIdian MR on first-line for in up higher robust were fractions fractions is prospective
We’ve MRIdian, needed patients turn better their our catchment courses program treatment, of This improved effects, life. XX. patients our radiation distinguishing has clinical therapy fewer driven our a in pandemic more Now with offering, company believe Slide shorter greatly treatment way. the patients adding several patients. positioned to recap the and this We’ve and Patients to quality fundamentally And exciting practice, add We’ve to thousands that, and changing detail. of over additional years. ourselves We’ve benefits the next market. review and Zach? our are work of times. area innovation in Slide from leaner. shortened and and to their outcomes, MRIdian things XX. By to new We provide potential We’ve benefiting now of to installation the to of To capitalized adding In outside lie improved come addressable the use financials of side hundreds come in it to service Zach summary, long ahead. out are and new value expand the stronger I’ll QX the with competitive of has customer potential net customers their their pipelines. patient within training. delivering treatment
